Drug-vs-Drug Verdicts: GLP-1 & Weight Loss Comparisons
Head-to-head verdicts on the most-searched GLP-1 drug pairings. Every comparison cell cites an FDA label (DailyMed), a peer-reviewed trial, or a current manufacturer price page.
Looking for provider-vs-provider comparisons or full provider rankings?
All drug-vs-drug verdicts
Wegovy vs Zepbound
semaglutide · tirzepatide
Zepbound delivered 20.9% TBWL in SURMOUNT-1 vs Wegovy's 14.9% in STEP-1 — and SURMOUNT-5 head-to-head confirmed Zepbound −20.2% vs Wegovy −13.7% over 72 weeks.
Last verified 2026-05-27
Ozempic vs Mounjaro
semaglutide · tirzepatide
SURPASS-2 head-to-head: Mounjaro 15mg dropped weight 11.2 kg vs Ozempic 1mg's 5.7 kg at 40 weeks. Ozempic wins on proven CV outcomes (SUSTAIN-6 MACE -26%).
Last verified 2026-05-27
Semaglutide vs Tirzepatide
semaglutide · tirzepatide
SURMOUNT-5 head-to-head: tirzepatide -20.2% body weight vs semaglutide -13.7% at 72 weeks. Semaglutide wins on CV outcomes (SELECT -20% MACE). Compare mechanisms and access.
Last verified 2026-05-27
Rybelsus vs Ozempic
semaglutide (oral) · semaglutide (subcutaneous)
Rybelsus is oral semaglutide (3/7/14 mg daily); Ozempic is injectable semaglutide (0.25-2 mg weekly). Same molecule — oral bioavailability ~1% means injection delivers more drug.
Last verified 2026-05-27
Mounjaro vs Zepbound
tirzepatide · tirzepatide
Mounjaro and Zepbound are the same molecule (tirzepatide) from Eli Lilly — Mounjaro is FDA-labeled for type 2 diabetes; Zepbound for obesity and obstructive sleep apnea.
Last verified 2026-05-27
Foundayo vs Rybelsus
orforglipron · semaglutide (oral)
Foundayo (orforglipron) is the first non-peptide oral GLP-1 — no food restriction, 11-12% weight loss in ATTAIN-1. Rybelsus is oral semaglutide — strict 30-min fast, T2D-only.
Last verified 2026-05-27
Mounjaro vs Wegovy
tirzepatide · semaglutide
Mounjaro is FDA-labeled for type 2 diabetes only; Wegovy is FDA-labeled for obesity + CV risk reduction. SURMOUNT-5 head-to-head: tirzepatide -20.2% vs semaglutide -13.7%.
Last verified 2026-05-27
Ozempic vs Zepbound
semaglutide · tirzepatide
Ozempic is labeled for type 2 diabetes; Zepbound for obesity and OSA. SURMOUNT-5 head-to-head: tirzepatide -20.2% vs semaglutide -13.7% at 72 weeks.
Last verified 2026-05-27
Wegovy vs Ozempic
semaglutide · semaglutide
Wegovy and Ozempic are the same molecule (semaglutide) from Novo Nordisk — Wegovy is FDA-labeled for obesity (max 2.4 mg); Ozempic for type 2 diabetes (max 2 mg).
Last verified 2026-05-27
Zepbound vs Foundayo
tirzepatide · orforglipron
Zepbound (tirzepatide) injection delivers ~22.5% TBWL vs Foundayo (orforglipron) oral pill ~11% — but Foundayo skips needles and has no food restriction.
Last verified 2026-05-27
Wegovy vs Foundayo
semaglutide · orforglipron
Wegovy delivered −14.9% TBWL in STEP-1 (68 wk weekly injection); Foundayo delivered −11.1% in ATTAIN-1 (72 wk, 17.2 mg oral). Wegovy adds SELECT CV benefit; Foundayo skips needles.
Last verified 2026-05-27
Ozempic vs Foundayo
semaglutide · orforglipron
Ozempic is weekly semaglutide injection (T2D label, SUSTAIN-6 CV benefit). Foundayo is the first non-peptide oral GLP-1 (obesity label 2025, 11-12% TBWL in ATTAIN-1).
Last verified 2026-05-27
Wegovy vs Saxenda
semaglutide · liraglutide
STEP-8 head-to-head: Wegovy 2.4 mg weekly produced -15.8% body weight vs Saxenda 3.0 mg daily -6.4% at 68 weeks. Same manufacturer, weekly beats daily.
Last verified 2026-05-28
Ozempic vs Trulicity
semaglutide · dulaglutide
SUSTAIN-7 head-to-head: Ozempic 1 mg cut A1C 1.8% and weight 6.5 kg vs Trulicity 1.5 mg's 1.4% and 3.0 kg. Trulicity wins on pediatric label and AWARD-7 kidney data.
Last verified 2026-05-28
Trulicity vs Mounjaro
dulaglutide · tirzepatide
Both made by Eli Lilly. Mounjaro 15 mg cut A1C ~2.3% and weight ~12.4% in SURPASS trials vs Trulicity 1.5 mg ~1.1% A1C and ~3 kg. Trulicity keeps the CV outcome label (REWIND) and a pediatric indication.
Last verified 2026-05-28
Trulicity vs Wegovy
dulaglutide · semaglutide
Wegovy delivered -14.9% body weight in STEP-1 vs Trulicity's ~3 kg in T2D trials. Trulicity wins on T2D CV outcomes (REWIND, MACE -12%) and pediatric coverage from age 10.
Last verified 2026-05-28
Saxenda vs Zepbound
liraglutide · tirzepatide
Saxenda (daily liraglutide 3 mg) delivered ~8% weight loss in SCALE; Zepbound (weekly tirzepatide) hit 20.9% in SURMOUNT-1. Saxenda keeps the pediatric and pregnancy-planning niches.
Last verified 2026-05-28
Rybelsus vs Trulicity
semaglutide (oral) · dulaglutide
Rybelsus is oral semaglutide (daily, 30-minute fast required); Trulicity is weekly dulaglutide injection. Both T2D-only — compare A1C, CV outcomes, pediatric label, cost.
Last verified 2026-05-28
Foundayo vs Mounjaro
orforglipron · tirzepatide
Foundayo (orforglipron) is Lilly's new daily oral non-peptide GLP-1 — FDA-approved for obesity April 2026, -11.1% TBWL in ATTAIN-1. Mounjaro is the weekly tirzepatide injection labeled for T2D only.
Last verified 2026-05-28
Saxenda vs Foundayo
liraglutide · orforglipron
Saxenda is daily liraglutide injection (~7-8% weight loss in SCALE Obesity). Foundayo is daily oral orforglipron (-11.1% TBWL in ATTAIN-1) — no fasting, adults only.
Last verified 2026-05-28
Saxenda vs Ozempic
liraglutide · semaglutide
Both Novo Nordisk GLP-1s, different labels: Saxenda 3 mg daily for obesity (SCALE -8%); Ozempic 0.25-2 mg weekly for T2D + CV risk (SUSTAIN-6 MACE -26%).
Last verified 2026-05-28
Mounjaro vs Saxenda
tirzepatide · liraglutide
Mounjaro is weekly tirzepatide for type 2 diabetes; Saxenda is daily liraglutide for obesity. Different drugs, different labels, different schedules — patients rarely choose between them.
Last verified 2026-05-28
Rybelsus vs Zepbound
semaglutide (oral) · tirzepatide
Rybelsus is daily oral semaglutide for T2D only (~3-5% weight loss, strict 30-min fast). Zepbound is weekly injectable tirzepatide for obesity and OSA (~20.9% weight loss).
Last verified 2026-05-28
Rybelsus vs Mounjaro
semaglutide (oral) · tirzepatide
Rybelsus 14 mg daily oral semaglutide drops A1C ~1.0%; Mounjaro 15 mg weekly injection drops A1C ~2.3% and weight ~12 kg. Both labeled for T2D only. Compare routes, magnitudes, and cost.
Last verified 2026-05-28
Wegovy vs Mounjaro
semaglutide · tirzepatide
Wegovy is obesity-labeled semaglutide; Mounjaro is T2D-labeled tirzepatide. The apples-to-apples obesity comparator for Mounjaro is Zepbound (same molecule, weight-loss label).
Last verified 2026-05-28
Foundayo vs Trulicity
orforglipron · dulaglutide
Foundayo (orforglipron) is Lilly's first oral non-peptide GLP-1, obesity-labeled with -11.1% TBWL in ATTAIN-1. Trulicity (dulaglutide) is the older weekly injectable with proven CV and CKD outcomes.
Last verified 2026-05-28
Saxenda vs Trulicity
liraglutide · dulaglutide
Saxenda is Novo's daily liraglutide 3.0 mg for obesity (SCALE -7-8%). Trulicity is Lilly's weekly dulaglutide for type 2 diabetes (REWIND MACE -12%). Different labels, frequencies, molecules.
Last verified 2026-05-28
Wegovy vs Contrave
semaglutide · naltrexone-bupropion
Wegovy delivers about -14.9% body weight at 68 weeks (STEP-1) vs about -6.1% at 56 weeks for Contrave (COR-I) — but Contrave is oral and roughly $400/mo cheaper.
Last verified 2026-05-28
Zepbound vs Contrave
tirzepatide · naltrexone-bupropion
Zepbound delivers roughly 3-4x more weight loss than Contrave (-20.9% vs -6.1%) but costs 4-5x more. Contrave is fully oral and cheaper at ~$99/mo.
Last verified 2026-05-28
Wegovy vs Qsymia
semaglutide · phentermine-topiramate
Wegovy 2.4 mg weekly produced -14.9% body weight in STEP-1 vs Qsymia 15/92 mg producing -10.9% in EQUIP. Weekly injection vs daily pill, REMS contraception required for Qsymia.
Last verified 2026-05-28
Zepbound vs Qsymia
tirzepatide · phentermine-topiramate
Zepbound (tirzepatide) delivers ~20.9% weight loss vs Qsymia's ~10.9%, but Qsymia is oral, cheaper, and REMS-restricted for pregnancy risk. Side-by-side verdict.
Last verified 2026-05-28
Contrave vs Qsymia
naltrexone-bupropion · phentermine-topiramate
Qsymia delivers more weight loss (about -9.8 to -10.9% at 56 weeks) than Contrave (-6.1% in COR-I), but Contrave is cheaper and has no REMS contraception requirement.
Last verified 2026-05-28
Ozempic vs Contrave
semaglutide · naltrexone-bupropion
Ozempic (semaglutide) is FDA-approved for type 2 diabetes, not weight loss; Contrave is an FDA-approved oral weight-loss drug. Cash price, efficacy, and indication compared.
Last verified 2026-05-28
Ozempic vs Qsymia
semaglutide · phentermine-topiramate
Weekly injectable semaglutide (off-label for weight loss) vs daily oral phentermine-topiramate ER (FDA-approved 2012, REMS-restricted). Trial data and cost compared.
Last verified 2026-05-28
Wegovy vs Rybelsus
semaglutide · oral semaglutide
Both are semaglutide from Novo Nordisk, but only Wegovy is FDA-approved for weight management. Wegovy delivers 2-3x more weight loss than oral Rybelsus at approved doses.
Last verified 2026-05-28
Zepbound vs Trulicity
tirzepatide · dulaglutide
Zepbound is FDA-approved for weight management (-20.9% at 72 weeks); Trulicity is FDA-approved for type 2 diabetes and CV risk, with only modest off-label weight loss.
Last verified 2026-05-28
Saxenda vs Rybelsus
liraglutide · oral semaglutide
Saxenda is FDA-approved for weight loss with -8.0% TBWL in SCALE; Rybelsus is T2D-only with modest off-label weight effects. Both daily from Novo Nordisk.
Last verified 2026-05-28
CagriSema vs Retatrutide
cagrilintide 2.4 mg + semaglutide 2.4 mg · retatrutide (LY3437943)
Both CagriSema and retatrutide are investigational drugs showing >20% weight loss in trials, but no head-to-head data exist and neither is FDA-approved.
Last verified 2026-07-06
Retatrutide vs Zepbound
retatrutide (LY3437943) · tirzepatide
Retatrutide's Phase 2 trial showed ~24% weight loss versus Zepbound's proven 21% in SURMOUNT-1, but retatrutide is unapproved and unavailable outside clinical trials.
Last verified 2026-07-06
CagriSema vs Wegovy
cagrilintide + semaglutide · semaglutide
CagriSema (investigational dual amylin+GLP-1, phase 3) vs Wegovy (FDA-approved semaglutide 2.4 mg): efficacy, CV outcomes, and availability.
Last verified 2026-07-06
CagriSema vs Zepbound
cagrilintide + semaglutide · tirzepatide
CagriSema (investigational, phase 3, ~20.4% weight loss) vs Zepbound (FDA-approved dual GIP/GLP-1, up to ~20.9%): a near-even efficacy matchup.
Last verified 2026-07-06
Survodutide vs Retatrutide
survodutide (BI 456906) · retatrutide (LY3437943)
Two investigational pipeline drugs compared across mechanism, phase-2/3 weight loss data, MASH evidence, and trial stage — no head-to-head data exists.
Last verified 2026-07-06
Mazdutide vs Retatrutide
mazdutide (IBI362 / LY3305677) · retatrutide (LY3437943)
Two investigational Eli Lilly-partnered drugs compared on mechanism, weight-loss data, trial stage, and geographic reach — cross-trial only, no head-to-head.
Last verified 2026-07-06